KA-5377

KA-5377: sourced facts only. name: "KA-5377 is a novel bispecific antibody (BsAb) developed to target CD19 and human 4-1BB, addressing the challenge of dose-limiting toxicity associated with traditional 4-1BB agonist cancer immunotherapy." [DOI:10.1158/1538-7445.am2025-6088]; target: "KA-5377 is a novel bispecific antibody (BsAb) developed to target CD19 and human 4-1BB, addressing the challenge of dose-limiting toxicity associated with traditional 4-1BB agonist cancer immunotherapy." [DOI:10.1158/1538-7445.am2025-6088]; target: "KA-5377 is a novel bispecific antibody (BsAb) developed to target CD19 and human 4-1BB, addressing the challenge of dose-limiting toxicity associated with traditional 4-1BB agonist cancer immunotherapy." [DOI:10.1158/1538-7445.am2025-6088]; developer: "Kyinno Biotechnology Co., Ltd, Beijing, China." [DOI:10.1158/1538-7445.am2025-6088]; modality: "KA-5377 is a novel bispecific antibody (BsAb) developed to target CD19 and human 4-1BB, addressing the challenge of dose-limiting toxicity associated with traditional 4-1BB agonist cancer immunotherapy." [DOI:10.1158/1538-7445.am2025-6088]; stage: "In PBMC-humanized immunodeficient mouse tumor models, KA-5377 improves the cytotoxic activity of bispecific antibodies targeting CD20 and CD3 against WSU-DLCL2 tumors, which highly express CD19." [DOI:10.1158/1538-7445.am2025-6088]